Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Teladoc Dropped 12.2% in September

By Jim Halley – Oct 5, 2021 at 11:41PM

Key Points

  • The stock is down more than 37% this year.
  • The company, despite rising revenue, is not profitable.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors may be worried about whether the company can hold onto COVID-related gains.

What happened

Shares of online healthcare company Teladoc (TDOC -3.40%) dropped 12.2% in September according to data provided by S&P Global Market Intelligence. The stock opened at $144.86 per share on Sept. 1 and closed at $126.81 on Sept. 30, the final day in the month that markets were open; and it never really rallied throughout the month.

A doctor giving a video consultation on a tablet.

Image source: Getty Images.

So what

Investors are seeing the stock as too COVID dependent, in that its business plan is reliant on people staying at home and out of their doctors' offices. From 2018 to 2019, the company's annual revenue climbed 32%, but last year, once the pandemic hit, Teladoc's annual revenue rose 97.8%.

Though the company is still seeing growth this year, with reported revenue of $954.8 million through six months, up 1,264% year over year, many are concerned that growth can't be sustained once people go back to work and return in-person to their doctors' offices.

There's another concern in that the company isn't getting closer to making a profit. Through six months, the company had a net loss of $333.4 million, or $2.16 per share, compared to a net loss of $55.2 million and $0.74 per share through the first six months of 2020.

The last worry is that big-time competitors are coming for the company's market share. Just this year, insurer Cigna, through its Evernorth division, purchased MDLive; Amazon greatly expanded Amazon Care; and Walmart has a purchase of MeMD in the works.

Now what

Few people doubt there's a big future for telehealth, even after the pandemic. A report by the Center for Connected Medicine found that while health systems expect telemedicine to decline once the pandemic ebbs, they still plan to expand telehealth services in the future.

Teladoc isn't likely going away either, with its early-to-market advantage and a brand name that has become synonymous with telehealth. However, this healthcare stock play is definitely for the long-term investor, as it may be a while until the company is making a profit.

In the meantime, its rapid revenue growth may slow, but the company is continuing to add subscribers. Through six months, its subscription revenue alone was 47% higher than last year. I think this shows that now that people have seen the possibilities of Teladoc, it has a greater chance of adoption by individuals and by companies.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jim Halley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and Teladoc Health. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.60 (-3.40%) $0.97
Walmart Inc. Stock Quote
Walmart Inc.
$153.07 (0.43%) $0.65
Amazon Stock Quote
$93.41 (-0.77%) $0.72
Cigna Stock Quote
$323.90 (1.27%) $4.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.